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Summary
Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We 
studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.
Methods We assessed the –1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in 
relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared 
disease risk for genetically-raised triglyceride concentration (20 842 patients with coronary heart disease, 
35 206 controls) with that recorded for equivalent diﬀ erences in circulating triglyceride concentration in prospective 
studies (302 430 participants with no history of cardiovascular disease; 12 785 incident cases of coronary heart 
disease during 2·79 million person-years at risk). We analysed –1131T>C in 1795 people without a history of 
cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear 
magnetic resonance spectroscopy.
Findings The minor allele frequency of –1131T>C was 8% (95% CI 7–9). –1131T>C was not signiﬁ cantly associated 
with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol 
(mean diﬀ erence per C allele 3·5% [95% CI 2·6–4·6]; 0·053 mmol/L [0·039–0·068]), lower apolipoprotein AI (1·3% 
[0·3–2·3]; 0·023 g/L [0·005–0·041]), and higher apolipoprotein B (3·2% [1·3–5·1]; 0·027 g/L [0·011–0·043]). By 
contrast, for every C allele inherited, mean triglyceride concentration was 16·0% (95% CI 12·9–18·7), or 0·25 mmol/L 
(0·20–0·29), higher (p=4·4×10–²⁴). The odds ratio for coronary heart disease was 1·18 (95% CI 1·11–1·26; p=2·6×10–⁷) 
per C allele, which was concordant with the hazard ratio of 1·10 (95% CI 1·08–1·12) per 16% higher triglyceride 
concentration recorded in prospective studies. –1131T>C was signiﬁ cantly associated with higher VLDL particle 
concentration (mean diﬀ erence per C allele 12·2 nmol/L [95% CI 7·7–16·7]; p=9·3×10–⁸) and smaller HDL particle 
size (0·14 nm [0·08–0·20]; p=7·0×10–⁵), factors that could mediate the eﬀ ects of triglyceride.
Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and 
coronary heart disease.
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Introduction
Whether conditions characterised by increased circulating 
triglyceride concentration (so-called triglyceride-mediated 
lipid pathways) are causal in coronary heart disease is 
uncertain. Prospective epidemiological studies have 
tended to report positive associations between circulating 
triglyceride concentration and risk of coronary heart 
disease,1 but these associations disappear after controlling 
for HDL and LDL (or non-HDL) cholesterol.2 However, 
because of limited understanding of the relevant 
biological pathways, interpretation of such adjustment is 
diﬃ  cult when making judgments about causality. If 
cholesterol in lipoproteins mediates any causal eﬀ ect of 
triglyceride, then controlling for it could obscure 
potentially relevant associations between triglyceride 
concentration and coronary heart disease. In the absence 
of such mediating eﬀ ects, however, failure to control for 
the confounding eﬀ ects of such closely related lipids 
would exaggerate these associations.3 In principle, 
randomised trials of triglyceride-lowering agents should 
be able to resolve this uncertainty. In practice, however, 
available interventions (eg, ﬁ brates, statins, nicotinic 
acid) cannot do so because they aﬀ ect several major lipids 
(eg, triglyceride, LDL cholesterol, HDL cholesterol).4
Studies of genetic variants that speciﬁ cally (or at least 
predominantly) aﬀ ect triglyceride concentration provide 
another route to assist with the judgment of causality. 
These studies exploit the fact that genotypes are ﬁ xed at 
conception and should be an indicator of lifelong lipid 
concentrations (ie, Mendelian randomisation analysis).5 
Genome-wide association studies have reported that 
polymorphisms in or near the apolipoprotein A5 (APOA5) 
gene are among the strongest known genetic determinants 
of triglyceride concentration.6 APOA5 is expressed in the 
liver and codes for apoAV—a 366 aminoacid protein that 
is predominantly associated with triglyceride-rich VLDL.7 
Previous studies have reported associations between 
–1131T>C (rs662799)—a regulatory variant in the 
promoter region of APOA5—and triglyceride con-
centration (webappendix pp 11–12). However, available 
studies have been insuﬃ  ciently powered to assess the 
magnitude and speciﬁ city of this association, or to 
establish its model of inheritance. Similar considerations 
apply to studies of –1131T>C and coronary heart disease 
See Online for webappendix
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(webappendix pp 11–12). Furthermore, available studies 
have been too small to assess reliably whether there is 
concordance between three separate associations: 
–1131T>C and triglyceride concentration; triglyceride 
concentration and risk of coronary heart disease; and 
–1131T>C and risk of coronary heart disease. If con-
cordance between these associations were to be shown, 
then it would lend support to causality.
We assessed APOA5 –1131T>C in relation to triglyceride 
concentration, several other risk factors, and risk of 
coronary heart disease to assess the likelihood of a causal 
relation between triglyceride-mediated path ways and this 
disease by study of this one genetic variant.
Methods
Study design and rationale
This study had four inter-related components. First, to 
assess suitability of study of –1131T>C as a method for 
deconfounding, we investigated its associations with 
triglyceride concentration, several other major lipids (ie, 
HDL and LDL cholesterol, apolipoproteins AI and B), 
and non-lipid risk factors. Second, we studied –1131T>C 
in 20 842 cases of coronary heart disease and 
35 206 controls. Third, we compared odds ratios (ORs) 
for coronary heart disease with genetically-raised 
triglyceride concentration versus hazard ratios (HRs) for 
this disease recorded with equivalent diﬀ erences in 
triglyceride concentration. Fourth, to provide mechanistic 
insight, we analysed –1131T>C in relation to lipoprotein 
characteristics in 1795 participants.
Contributing studies
For genetic analyses, we included 73 252 individuals from 
39 studies of –1131T>C (rs662799) identiﬁ ed through 
registry approaches8 and systematic searches of published 
work (webappendix pp 2, 10–13). According to a uniform 
protocol, all but one identiﬁ ed studies supplied data for: 
genotype frequencies by disease status (separately for 
myocardial infarction, non-overlapping coronary stenosis 
cases, and healthy controls); deﬁ nition of coronary heart 
disease; population sampling and laboratory procedures; 
and mean (SD) of lipid measures by genotype in people 
without cardiovascular disease at time of measurement. 
Because one study involving 154 participants (or 0·2% of 
the total) was unable to provide tabular data, information 
for it was abstracted from published reports (webappendix 
p 2). Genotyping was done with the ITMAT-Broad-CARe 
50K array,9 Taqman assay or similar platforms, and 
restriction fragment length polymorphism. Studies 
typically used standard lipid measurements (enzymatic 
assays for triglyceride; precipitation methods for HDL 
cholesterol; immuno assays for apolipoproteins). 
Lipoprotein particle concentration and diameter were 
assessed by nuclear magnetic resonance spectroscopy 
(LipoScience, Raleigh, NC, USA) in 1795 participants with 
no history of cardiovascular disease in the prospective 
EPIC-Norfolk Study.10 Myocardial infarction was deﬁ ned 
according to WHO criteria11 and coronary stenosis by 
angiography (at least 50% of ≥one major coronary artery; 
webappendix p 2). Associations of –1131T>C with several 
non-lipid vascular risk factors (ie, blood pressure, smoking 
status, body-mass index, history of diabetes) were assessed 
in 13 331 participants in prospective studies with no 
history of cardiovascular disease at the baseline survey.
For assessment of associations of triglyceride associa-
tion with incidence of coronary heart disease, we accessed 
individual participant data from 68 prospective studies of 
302 430 participants without known cardiovascular disease 
at baseline. 12 785 outcomes of incident fatal coronary 
heart disease and non-fatal myocardial infarction (with 
use of WHO criteria) were re corded during 2·79 million 
person-years at risk.2 Because measurement error or 
within-person variability (ie, regres sion-dilution bias) in 
triglyceride concentration and other risk factors can lead 
to misestimation of risk,12 we calculated long-term average 
(usual) concentrations of triglyceride and other risk factors 
from serial measurements (median interval 4·7 years 
[IQR 2·7–6·1]) for 89 073 partici pants, as described 
previously.12 Serial measurements yielded age-adjusted 
and sex-adjusted regression dilution ratios of 0·63 
(95% CI 0·60–0·67) for loge triglyceride, 0·69 (0·64–0·74) 
Figure 1: APOA5 –1131T>C genotypes and circulating lipid concentration
Size of data markers is proportional to the inverse of the variance of the weighted mean diﬀ erence (the 
reference group is represented by a square with an arbitrary ﬁ xed size) and the vertical lines represent 95% CIs. 
To enable comparison of associations across lipids and apolipoproteins, associations are presented as 
percentage diﬀ erences (calculated in reference to the weighted mean of each marker in common homozygotes). 
*Reference group.
Figure 2: Association of APOA5 –1131T>C with circulating lipid concentration per C allele
Size of data markers is proportional to the inverse of the variance of the weighted mean diﬀ erence, and the 
horizontal lines represent 95% CIs. To enable comparison of associations across lipids and apolipoproteins, 
associations are presented as percentage diﬀ erences (calculated in reference to the weighted mean of each marker 
in common homozygotes).
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for HDL cholesterol, and 0·64 (0·57–0·71) for directly 
measured LDL cholesterol.2 
Statistical analysis
We calculated estimates of association separately within 
each study before pooling across studies by random-
eﬀ ects meta-analysis (parallel analyses used ﬁ xed-eﬀ ect 
models). Summary ORs for coronary heart disease and 
mean concentrations of lipid markers (and diﬀ erences in 
mean concentrations compared with the common 
homozygotes on the original scale [ie, mmol/L for 
triglyceride, HDL cholesterol, and LDL cholesterol; g/L 
for apolipoproteins A and B]) were estimated. To enable 
comparisons across lipid measures, associations are also 
presented as percentage diﬀ erences (calculated in 
reference to the weighted mean of each marker in 
common homozygotes). For studies that compared the 
same control group to patients with myocardial infarction 
and (non-overlapping) patients with angiographically 
documented coronary stenosis, we avoided any double 
counting by analysing cases of myocardial infarction and 
coronary stenosis separately before combining them into 
one coronary disease group.
We estimated HRs for coronary heart disease with 
triglyceride concentration with Cox proportional hazard 
regression models, using methods described 
previously.2,13 HRs were adjusted progressively for age, 
sex, systolic blood pressure, smoking status, history of 
diabetes, body-mass index, non-HDL cholesterol, and 
HDL cholesterol. We calculated HRs for coronary heart 
disease with diﬀ erences in lipid concentration observed 
with –1131T>C to enable comparison with odds ratios for 
coronary heart disease with genetically-raised triglyceride 
concentration.
Heterogeneity was assessed by the I2 statistic,14 the 
Q statistic, and meta-regression of prespeciﬁ ed groupings 
of studies characteristics. Small-study eﬀ ects were 
assessed with funnel plots and by comparing pooled 
results from studies of at least 500 patients with coronary 
heart disease (or, for gene–lipid investigations, at least 
1000 healthy participants) with those from smaller 
studies. Analyses were done with Stata (version 11.0), 
two-sided p values, and 95% CIs.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. NS and JD had full access to all the 
data and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Of the 73 252 participants with information about APOA5 
–1131T>C, 47 784 (65%) were of European descent. The 
minor allele frequency of –1131T>C was 8% (95% CI 7–9) 
in people of European descent without coronary heart 
disease. –1131T>C was not signiﬁ cantly related to several 
non-lipid risk factors (webappendix p 3) or LDL 
cholesterol. For every C allele inherited, carriers had 
3·5% (95% CI 2·6–4·6), or 0·053 mmol/L (0·039–0·068), 
lower mean HDL cholesterol; 1·3% (0·3–2·3), or 
0·023 g/L (0·005–0·041), lower mean apolipoprotein AI; 
and 3·2% (1·3–5·1), or 0·027 g/L (0·011–0·043), higher 
mean apolipoprotein B (ﬁ gure 1 and ﬁ gure 2) than did 
non-carriers.
–1131T>C was strongly related to triglyceride 
concentration, consistent with a per-allele model of 
inheritance. Carriers of two C alleles had 32·6% (95% CI 
26·7–39·0), or 0·51 mmol/L (0·42–0·61), higher mean 
triglyceride than did non-carriers (ﬁ gure 1). For every 
C allele inherited, carriers had 16·0% (12·9–18·7), or 
0·25 mmol/L (0·20–0·29), higher mean triglyceride than 
did common homozygotes (p=4·4×10–²⁴; ﬁ gure 2). We 
noted signiﬁ cant heterogeneity in studies of triglyceride 
(I²=76%, 95% CI 67–83; p<0·0001), although little of it 
was explained by characteristics recorded here, including 
fasting status (webappendix p 5). We recorded no 
evidence of small-study eﬀ ects (webappendix pp 5–7). In 
the subset of participants who had detailed information 
about lipoproteins, –1131T>C was signiﬁ cantly associated 
with higher VLDL particle concentration, smaller HDL 
particle size, higher LDL particle concentration, and 
smaller LDL particle size (table).
The OR for coronary heart disease was 1·40 (95% CI 
1·12–1·75) in carriers of two C alleles compared with 
non-carriers (ﬁ gure 3), with evidence of a per-allele model 
of inheritance. The OR for coronary heart disease was 
1·18 (1·11–1·26; p=2·6×10–⁷) per C allele. We noted some 
heterogeneity in studies of coronary heart disease 
(I²=35%, 95% CI 0–59; p=0·03), although little of it was 
explained by characteristics recorded here, including type 
of coronary outcome (webappendix p 7). Exclusion of 
three studies that signiﬁ cantly (p<0·05) deviated from 
Hardy-Weinberg equilibrium among controls did not 
Genotype* β coeﬃ  cient (95% CI)† p value 
for trend
TT (n=1606) TC (n=182) CC (n=7)
LDL
Particle size (nm) 21·1 (0·6) 21·0 (0·6) 20·7 (0·4) –0·13 (–0·05 to –0·21) 0·002
Particle concentration 
(nmol/L)
1567 (418) 1680 (461) 1670 (435) 105 (44 to 166) 0·001
VLDL
Particle size (nm) 50·8 (8·4) 51·3 (7·9) 59·6 (6·7) 1·13 (–0·07 to 2·33) 0·065
Particle concentration 
(nmol/L)
93·0 (31·2) 106·1 (32·4) 106·6 (23·0) 12·2 (7·7 to 16·7) 9·3×10–8
HDL
Particle size (nm) 8·9 (0·5) 8·8 (0·4) 8·5 (0·3) –0·14 (–0·08 to –0·20) 7·0×10–5
Particle concentration 
(μmol/L)
34·0 (5·4) 33·9 (5·7) 35·8 (5·4) 0·04 (–0·7 to 0·8) 0·93
*Data are mean (SD). †Calculated from linear regression of each lipoprotein marker on APOA5 genotype. 
Table: APOA5 –1131T>C genotypes and lipoprotein particle size and concentration in controls in the 
EPIC-Norfolk Study10
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change the ﬁ ndings (data not shown). There were too 
few data for reliable analyses by ethnic origin, although 
we recorded no signiﬁ cant diﬀ erences in analyses of 
white versus non-white participants (webappendix 
pp 5 and 7).
In 302 430 participants in prospective studies, the HR 
for coronary heart disease, adjusted for age and sex only, 
was 1·10 (95% CI 1·08–1·12) per 16% higher triglyceride 
concentration. The HR reduced to 1·00 (0·98–1·02) after 
further adjustment for several risk factors. Most of the 
attenuation in the HR was due to adjustment for HDL 
cholesterol and non-HDL cholesterol (webappendix 
pp 4 and 8). The OR for coronary heart disease associated 
with –1131T>C was concordant with the HR that was 
recorded with triglyceride concentration, provided that 
the HR was not adjusted for HDL cholesterol and non-
HDL cholesterol (ﬁ gure 3). The association between 
–1131T>C and HDL cholesterol could account for a 
modest component of the association between –1131T>C 
and coronary heart disease (webappendix p 9).
Discussion
We have reported a series of ﬁ ndings that are consistent 
with a causal role for triglyceride-mediated pathways in 
coronary heart disease. First, we have shown that 
–1131T>C—a regulatory variant in APOA5—is 
unrelated to several non-lipid risk factors or LDL 
cholesterol, and comparatively moderately related to 
HDL cholesterol and other major lipids. Second, we 
have shown that –1131T>C is strongly related to 
triglyceride concentration in a dose-dependent manner, 
with every C allele increasing triglyceride by about as 
much as having type 2 diabetes mellitus.15 Third, in an 
analysis of 20 842 cases and 35 206 controls, we have 
shown that –1131T>C is related to risk of coronary heart 
disease in an analogous dose-dependent manner, with 
about 18% higher risk per C allele. Fourth, in an 
analysis of 302 430 people, we have shown that risk of 
coronary heart disease with genetically raised 
triglyceride is concordant with risk of disease with 
equivalent diﬀ erences in circulating triglyceride itself. 
Finally, we have shown that –1131T>C is associated 
with higher VLDL concentration and smaller HDL 
particle size—pathways through which triglyceride 
could aﬀ ect risk of coronary heart disease.
These ﬁ ndings encourage further study of interventions 
that target triglyceride-mediated pathways.16–19 Because 
preliminary studies have suggested that responses to 
ﬁ brates and statins might vary by APOA5 –1131T>C 
status,20–22 our data reinforce the need for more powerful 
such studies. Our results also have implications for 
observational studies. They suggest that, in attempts to 
understand the potential causal relevance of triglyceride 
to health outcomes, care is needed to avoid over-
adjustment for potential mediating pathways. By contrast, 
such considerations do not apply to the assessment of 
prediction of coronary heart disease, for which a main 
consideration is inclusion of characteristics that maximise 
a model’s predictive value. Previous analyses have 
suggested that, given knowledge of concentrations of 
HDL and total cholesterol, assessment of triglyceride 
concentration provides little incremental information for 
prediction of coronary heart disease.2
Our data are consistent with observations of premature 
atherosclerosis in patients with raised triglyceride con-
centration (eg, familial hypertriglyceridaemia, familial 
combined hyperlipidaemia, and remnant hyper-
lipidaemia).23–25 Disorders of high triglyceride concen-
tration could remodel LDL and HDL particles, making 
them smaller and denser.26,27 For LDL, such changes could 
make particles more atherogenic.28 For HDL, the situation 
is more complex, but small dense HDL might be 
functionally impaired (or even proatherogenic).29 
Hypertriglyceridaemia could be an indicator of increased 
concentration of proatherogenic VLDL and remnant 
lipoporoteins.30 These possibilities are consistent with 
our observation that –1131T>C is related to higher VLDL 
con centration and smaller HDL particle size.
APOA5 –1131T>C is in almost complete linkage 
disequilibrium with two other APOA5 polymorphisms 
in Europeans: +1891T>C (rs2266788) and –3A>G 
(rs651821).31 In-vitro studies suggest that these variants 
might act together because constructs of the haplotype 
carrying all three rare alleles are associated with about 
50% lower gene expression than the wild type haplotype, 
resulting in decreased synthesis and incorporation into 
triglyceride-rich particles of apoAV.32 ApoAV activates 
Figure 3: Association of APOA5 –1131T>C genotypes and equivalent diﬀ erences in circulating triglyceride 
concentration with risk of coronary heart disease
Non-lipid factors adjusted for included smoking status, systolic blood pressure, body-mass index, and history of 
diabetes (webappendix p 5). Size of data markers is proportional to the inverse of the variance of the weighted 
mean diﬀ erence (the reference group is represented by a square with an arbitrary ﬁ xed size) and the vertical lines 
represent 95% CIs. *Reference group. †Odds ratio for coronary heart disease associated with APOA5 –1131T>C. 
‡Hazard ratio for coronary heart disease in prospective studies for diﬀ erences in usual triglyceride concentration 
equal to those recorded with APOA5 –1131T>C (as reported in ﬁ gure 1).
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lipoprotein lipase33 (an enzyme central to triglyceride 
catabolism) and acts as a ligand for receptor clearance of 
triglyceride-rich particles.34 However, although –1131T>C 
could directly mediate changes in triglyceride 
concentration, detailed studies are needed to identify the 
causative genetic loci and to improve understanding of 
their functional role.
Causal investigation with use of APOA5 –1131T>C 
should be more reliable than conventional observational 
studies because genetically-raised triglyceride is: deter-
mined at conception, avoiding reverse causality; unrelated 
to several non-lipid risk factors and comparatively 
moderately related to HDL cholesterol and other lipids, 
reducing the scope for confounding; and presumably 
indicative of lifelong concentrations. This ﬁ nal consider-
ation might partly explain the possibly higher OR for 
coronary heart disease with genetically-raised tri glyceride 
than the HR with equivalent diﬀ erences in triglyceride 
concentration. Indeed, even estimation of long-term 
average lipid concentrations in midlife (as we did with 
serial measurements from 89 073 adults) might not 
necessarily approximate lifelong concentrations. Another 
potential explanation is that part of the association between 
–1131T>C and coronary heart disease indicates non-
triglyceride-mediated pathways. We noted, for example, 
comparatively moderate associations between –1131T>C 
and HDL cholesterol. However, because –1131T>C is a 
regulatory variant of APOA5 that is predominantly 
associated with triglyceride concentration, the scope for 
pleiotropy is reduced. Future studies should aim to include 
several (unlinked) genetic variants as deconfounding 
methods, because if they produce congruent predictions 
with respect to the causal eﬀ ect of triglycerides on coronary 
heart disease, then the scope for pleiotropy would be 
reduced still further.35
Although we used individual participant data for 
analyses of circulating triglyceride concentration and 
risk of coronary heart disease, we had access only to 
tabular genetic data, thereby preventing adjustment of 
associations between –1131T>C and coronary heart 
disease for lipids, or instrumental variables analysis. 
Since most participants were of European descent, 
further studies are needed in other races. Mechanistic 
studies are needed that include more extensive 
genotyping of APOA5 (and related loci) and lipoprotein 
assessment. Future studies should also assess whether 
triglyceride-related genotypes are related to liver function 
or accumulation of liver fat, since some triglyceride-
modifying agents could promote hepatic dysfunction.36
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